Eppley Institute for Research in Cancer and Allied Diseases, University at Nebraska Medical Center, Omaha, USA.
BMC Cancer. 2012 Jun 6;12:221. doi: 10.1186/1471-2407-12-221.
TGFβ signaling has typically been associated with suppression of tumor initiation while the role it plays in metastasis is generally associated with progression of malignancy. However, we present evidence here for an anti-metastatic role of TGFβ signaling.
To test the importance of TGFβ signaling to cell survival and metastasis we compared human colon carcinoma cell lines that are either non-tumorigenic with TGFβ response (FET), or tumorigenic with TGFβ response (FETα) or tumorigenic with abrogated TGFβ response via introduction of dominant negative TGFβRII (FETα/DN) and their ability to metastasize. Metastatic competency was assessed by orthotopic transplantation. Metastatic colony formation was assessed histologically and by imaging.
Abrogation of TGFβ signaling through introduction of a dominant negative TGFβ receptor II (TGFβRII) in non-metastatic FETα human colon cancer cells permits metastasis to distal organs, but importantly does not reduce invasive behavior at the primary site. Loss of TGFβ signaling in FETα-DN cells generated enhanced cell survival capabilities in response to cellular stress in vitro. We show that enhanced cellular survival is associated with increased AKT phosphorylation and cytoplasmic expression of inhibitor of apoptosis (IAP) family members (survivin and XIAP) that elicit a cytoprotective effect through inhibition of caspases in response to stress. To confirm that TGFβ signaling is a metastasis suppressor, we rescued TGFβ signaling in CBS metastatic colon cancer cells that had lost TGFβ receptor expression due to epigenetic repression. Restoration of TGFβ signaling resulted in the inhibition of metastatic colony formation in distal organs by these cells. These results indicate that TGFβ signaling has an important role in the suppression of metastatic potential in tumors that have already progressed to the stage of an invasive carcinoma.
The observations presented here indicate a metastasis suppressor role for TGFβ signaling in human colon cancer cells. This raises the concern that therapies targeting inhibition of TGFβ signaling may be imprudent in some patient populations with residual TGFβ tumor suppressor activity.
TGFβ 信号通常与肿瘤起始的抑制有关,而其在转移中的作用通常与恶性肿瘤的进展有关。然而,我们在这里提供了 TGFβ 信号具有抗转移作用的证据。
为了测试 TGFβ 信号对细胞存活和转移的重要性,我们比较了人结肠癌细胞系,这些细胞系要么具有 TGFβ 反应的非致瘤性(FET),要么具有 TGFβ 反应的致瘤性(FETα),要么通过引入显性负 TGFβRII(FETα/DN)而致瘤性被阻断且缺乏 TGFβ 反应,并用它们的转移能力进行比较。通过原位移植评估转移能力。通过组织学和成像评估转移集落的形成。
通过在非转移性 FETα 人结肠癌细胞中引入显性负 TGFβ 受体 II(TGFβRII)阻断 TGFβ 信号,允许转移到远处器官,但重要的是,不会减少原发性部位的侵袭行为。在 FETα-DN 细胞中失去 TGFβ 信号会导致细胞在体外受到应激时增强细胞存活能力。我们表明,细胞存活能力的增强与 AKT 磷酸化和凋亡抑制因子(IAP)家族成员(存活素和 XIAP)的细胞质表达增加有关,这些成员通过抑制应激反应中的半胱天冬酶来产生细胞保护作用。为了确认 TGFβ 信号是一种转移抑制物,我们在 CBS 转移性结肠癌细胞中拯救了 TGFβ 信号,这些细胞由于表观遗传抑制而失去了 TGFβ 受体表达。恢复 TGFβ 信号导致这些细胞在远处器官中形成转移集落的能力受到抑制。这些结果表明,TGFβ 信号在已经进展为侵袭性癌阶段的肿瘤中具有抑制转移潜力的重要作用。
这里提出的观察结果表明 TGFβ 信号在人结肠癌细胞中具有转移抑制作用。这引起了人们的关注,即针对抑制 TGFβ 信号的治疗在一些具有残留 TGFβ 肿瘤抑制活性的患者群体中可能是不明智的。